meetings industry association of australia |
||||
|
meetings industry association of australia News for 14-Aug-25 Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General |
The Best meetings industry association of australia websiteAll the meetings industry association of australia information you need to know about is right
here. Presented and researched by http://www.mdnewscast.net. We've searched
the information super highway far and wide to provide you with the
best meetings industry association of australia site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
meetings industry association of australia
Do You Dare To Ask Jeeves about meetings industry association of australia ? Well you can sure do this if you want to find out about meetings industry association of australia but we have made your life much easier. This is our favorite Net Butler and he answers detailed questions about anything. We put him to the test and asked several questions about meetings industry association of australia. Jeeves give his answers in several ways. Some of the answers are from companies promoting meetings industry association of australia. These answers are some that we have reviewed in our research of meetings industry association of australia and in an effort to find the best value available. Well we asked and here is the very best of the best sites. meetings industry association of australia
While the threat from hackers is low for individuals, a more serious threat to personal privacy comes from unscrupulous meetings industry association of australia companies that operate websites for quick quids. Many meetings industry association of australia sites require you to register before you can use its services. Often you must provide personal information, such as your name, street address, and e-mail address. Then as you browse the site, data is collected as to which pages you visited, how long you remained on each page, the links you clicked, what terms you searched, and so on. After a number of visits to the site, a personal profile emerges. The question is, what do meetings industry association of australia site operators do with this information? Most claim that they use it to personalize your experience on the site. For instance, if a meetings industry association of australia site learns that you are interested in meetings industry association of australia, the next time you visit the site, you might be presented with an article or advertisements for that and related products. But some meetings industry association of australia websites sell this information to marketers, which means that you may find yourself receiving unwanted catalogs from garden suppliers. Our preferred retailer does not do this. a Cold; Starve a Tumor by: ARA Content
(ARA) - One of the most exciting developments in modern medicine has been the discovery that cancerous tumors have the potential of being "starved" out of existence, or at least into dormancy. Scientists, doctors and, of course, patients, are all anticipating the prospect that cancer patients may take a drug that will stop a tumor in its track by cutting off the blood supply that nourishes it. At the core of this medical breakthrough was the discovery that every tumor needs to "recruit" its own blood supply to flourish and grow. Scientists also found out that tumors actively "participated" in this process by secreting certain growth chemicals that would attract blood vessels to the tumor. Having identified this process, the next step was to determine if drugs could be created that could somehow arrest or reverse the progress of blood vessels amassing around a tumor. The result has been a highly dynamic and exciting area of medicine called anti-angiogenesis (meaning "against the formation of new blood vessels") that focuses on inhibiting the growth of cancer by developing drugs that will prevent tumors from growing in size. Currently, there are several drug companies that are on the cusp of introducing drugs that will work by the process of anti-angiogenesis. Generally speaking, the drugs seek to improve survival rates of cancer patients, as well as increase the length of time that patients survive. And unlike conventional cancer therapies that have punishing side effects, the new drugs seem to demonstrate few or no side effects for most people. Furthermore, some of the studies show that by utilizing both conventional treatments like radiation and/or chemotherapy in conjunction with anti-angiogenesis drugs, the cumulative effect is even more powerful. One highly regarded company that is at the forefront of developing anti-angiogenesis drugs is Aeterna Laboratories, based in Quebec, Canada and traded on the Nasdaq market under the ticker symbol, AELA. The company's premier product, Neovastat, is currently being tested in clinical trials for a variety of cancers including lung, renal (kidney) and multiple myeloma (bone marrow). The results for the renal and multiple myeloma tests are scheduled to wrap up by the end of 2002 and, if conclusive, will be submitted to the Federal Drug Administration for review. Out of all the drugs under development, Neovastat is unique because of its multi-functionality, which is its ability to shut down two pathways recognized as being responsible for promoting angiogenesis (in contrast to other drugs which just block one pathway). In clinical trials, Neovastat has been shown to have no side effects in most people. This is obviously a big advantage for people who know the agony of nausea, exhaustion and/or hair loss that can accompany chemotherapy drugs. In tests, Neovastat has been given to people in liquid oral form, generally the preferable form of drug delivery for patients. If you are a cancer patient interested in clinical trial participation, you can get information about current trials by calling (888)-349-3232 If you are an oncologist, please contact Claude Hariton, Ph.D., vice president of Clinical and Regulatory Affairs at (418) 652-8525 ext. 306. To learn more about anti-angiogenesis drugs and Aeterna Laboratories, visit the Aeterna Web site at www.aeterna.com.
|
|||
|
http://www.medmeet.com/ |
||||
| Internet Meetings Listen On The Net Medical Meetings |